{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:01:44Z","timestamp":1778677304149,"version":"3.51.4"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.ijcard.2011.10.104","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T22:56:08Z","timestamp":1321570568000},"page":"5-18","source":"Crossref","is-referenced-by-count":17,"title":["Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk"],"prefix":"10.1016","volume":"163","author":[{"given":"Jean-Pierre","family":"Bassand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2011.10.104_bb0005","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0010","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Bassand","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0015","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.jacc.2009.10.015","volume":"54","author":"Kushner","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0020","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology","volume":"29","author":"Van de Werf","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","article-title":"A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin","volume":"42","author":"The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0035","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0002-9149(03)00972-X","article-title":"Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions","volume":"92","author":"Kinnaird","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0040","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0195-668X(03)00485-8","article-title":"Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE)","volume":"24","author":"Moscucci","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0045","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","article-title":"Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes","volume":"96","author":"Rao","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0050","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0055","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.08-0673","article-title":"New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Weitz","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0060","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein-coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/ATVBAHA.107.150474","article-title":"Cell adhesion mechanisms in platelets","volume":"28","author":"Varga-Szabo","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0070","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.124.3_suppl.4S","article-title":"Thrombin formation","volume":"124","author":"Mann","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0075","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/01.RES.0000264509.36234.51","article-title":"Clinical aspects of platelet inhibitors and thrombus formation","volume":"100","author":"Meadows","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-2005-916671","article-title":"Platelets: physiology and biochemistry","volume":"31","author":"Jurk","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.blre.2006.06.001","article-title":"Platelet\u2013neutrophil-interactions: linking hemostasis and inflammation","volume":"21","author":"Zarbock","year":"2007","journal-title":"Blood Rev"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V100.1.148","article-title":"Thrombin functions during tissue factor-induced blood coagulation","volume":"100","author":"Brummel","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0095","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","author":"Coughlin","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0100","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1101\/gad.9.16.2020","article-title":"Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice","volume":"9","author":"Suh","year":"1995","journal-title":"Genes Dev"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0105","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1124\/jpet.102.042663","article-title":"Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates","volume":"304","author":"Derian","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(03)01973-3","article-title":"Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig","volume":"473","author":"Kato","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0115","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2147\/VHRM.S3266","article-title":"Emergence of new oral antithrombotics: a critical appraisal of their clinical potential","volume":"4","author":"Lassen","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0120","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0125","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/ncpcardio1372","article-title":"Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future","volume":"5","author":"Raju","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCULATIONAHA.106.685974","article-title":"Beyond unfractionated heparin and warfarin: current and future advances","volume":"116","author":"Hirsh","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0135","first-page":"60","article-title":"The novel anticoagulants: entering a new era","volume":"139","author":"Bounameaux","year":"2009","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0140","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1161\/circ.113.10.e409","volume":"113","author":"Sacco","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0145","doi-asserted-by":"crossref","first-page":"670S","DOI":"10.1378\/chest.08-0691","article-title":"Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Harrington","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/1120090-000000000-00000","article-title":"Argatroban: a review of its use in the management of heparin-induced thrombocytopenia","volume":"9","author":"Dhillon","year":"2009","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0155","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0160","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0165","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0170","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0175","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.carrev.2008.08.001","article-title":"Major bleeding complicating contemporary primary percutaneous coronary interventions-incidence, predictors, and prognostic implications","volume":"10","author":"Fuchs","year":"2009","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0180","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ahj.2007.10.002","article-title":"Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy","volume":"155","author":"Chew","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0185","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1161\/CIRCULATIONAHA.108.787143","article-title":"Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding","volume":"118","author":"Wang","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0190","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/CIRCULATIONAHA.107.694273","article-title":"Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?","volume":"116","author":"Spencer","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0195","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/eurheartj\/ehp401","article-title":"Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes","volume":"31","author":"Bassand","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0200","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.292.13.1555","article-title":"Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes","volume":"292","author":"Rao","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0205","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0210","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0215","doi-asserted-by":"crossref","first-page":"708S","DOI":"10.1378\/chest.08-0665","article-title":"Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Goodman","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0220","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0225","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0230","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0235","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0240","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0245","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0250","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","article-title":"Early and late effects of clopidogrel in patients with acute coronary syndromes","volume":"107","author":"Yusuf","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0255","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0260","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0265","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0270","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0275","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.297.6.591","article-title":"Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial","volume":"297","author":"Stone","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0280","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1741-7015-8-36","article-title":"Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis","volume":"8","author":"Geeganage","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0285","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.amjcard.2010.03.012","article-title":"Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"106","author":"Ottani","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2009.08.093","article-title":"Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial","volume":"56","author":"Zeymer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0295","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0300","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0305","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0310","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0315","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0320","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(08)60422-5","volume":"371","author":"Wiviott","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0325","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0330","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0335","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0340","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0345","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1160\/TH09-03-0192","article-title":"Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis","volume":"102","author":"Jennings","year":"2009","journal-title":"Thromb Haemost"},{"issue":"Suppl IV","key":"10.1016\/j.ijcard.2011.10.104_bb0350","first-page":"IV-280","article-title":"Anti-thrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs","volume":"108","author":"Kogushi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0355","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1160\/TH08-12-0805","article-title":"The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease","volume":"102","author":"Serebruany","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0360","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","article-title":"Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease","volume":"31","author":"Goto","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0365","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","article-title":"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity","volume":"51","author":"Chackalamannil","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0370","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study","volume":"373","author":"Becker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0375","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ahj.2009.07.001","article-title":"The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale","volume":"158","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0380","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2009.06.027","volume":"158","author":"Morrow","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0385","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1161\/CIRCULATIONAHA.111.021733","article-title":"Inhibitors of the platelet thrombin receptor: will they live up to their promises?","volume":"123","author":"Van de Werf","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0390","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0395","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1161\/CIRCULATIONAHA.105.573550","article-title":"Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials","volume":"112","author":"Eikelboom","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0400","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0405","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.293.4.427","article-title":"Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation","volume":"293","author":"Yusuf","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0410","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/eurheartj\/ehm224","article-title":"Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis","volume":"28","author":"Murphy","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0415","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0420","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0425","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2007.07.042","article-title":"Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial","volume":"50","author":"Mehta","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0430","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0435","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1538-7836.2009.03705.x","article-title":"Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial","volume":"8","author":"Anderson","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0440","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.2010.1320","article-title":"Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA\/OASIS-8 randomized trial","volume":"304","author":"Steg","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0445","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0450","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0455","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0460","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0465","series-title":"American Heart Association (AHA) 2009 Congress November 14\u201318, 2009. Orlando, FL","article-title":"Randomized dagibatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel","author":"Oldgren","year":"2009"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0470","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0475","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0480","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0485","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"Gibson","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2011.10.104_bb0490","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ahj.2006.08.002","volume":"152","author":"White","year":"2006","journal-title":"Am Heart J"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527311019784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527311019784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T19:17:58Z","timestamp":1560971878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527311019784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0167527311019784"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2011.10.104","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}